Follow the people · Insider
Shane Barton
Shane Barton files insider transactions with the SEC as a principal accounting officer of BioAge Labs (BIOA). We hold 2 disclosed purchases and sales filed since 9 June 2021, 2 of them in the last 90 days.
- Files forBIOA
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure1 July 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 27 September 2024 — 30 June 2026Principal Accounting Officer · BioAge Labs (BIOA)23 Form 4 lines · source: SEC Form 4
- Filed 26 February 2021 — 7 June 2023VP & Corporate Controller · Precision Biosciences (DTIL)14 Form 4 lines · source: SEC Form 4
Everything they disclosed
37 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 9,301 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- ▼ sold on the open market 20,216 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- exercised options over 9,301 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 29 June 2026 · filed 1 July 2026
- exercised options over 7,261 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 29 June 2026 · filed 1 July 2026
- exercised options over 8,958 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 29 June 2026 · filed 1 July 2026
- exercised options over 14,198 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 29 June 2026 · filed 1 July 2026
- exercised options over 4,290 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 1 July 2026
- exercised options over 4,000 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 1 July 2026
- exercised options over 4,065 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 1 July 2026
- exercised options over 7,861 shares of BioAge Labs (a derivative holding)SEC Form 41 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 1 July 2026
- exercised options over 7,261 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- exercised options over 8,958 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- exercised options over 14,198 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- ▼ sold on the open market 42,350 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 29 June 2026 · filed 1 July 2026
- exercised options over 4,290 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- exercised options over 4,000 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- exercised options over 4,065 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- exercised options over 7,861 shares of BioAge LabsSEC Form 41 July 2026Common Stock · traded 30 June 2026 · filed 1 July 2026
- was granted 45,000 shares of BioAge Labs (a derivative holding)SEC Form 419 February 2026Stock Option (Right to Buy) · traded 17 February 2026 · filed 19 February 2026
- was granted 45,000 shares of BioAge Labs (a derivative holding)SEC Form 419 February 2026Stock Option (Right to Buy) · traded 17 February 2026 · filed 19 February 2026
- ▲ bought on the open market 2,632 shares of BioAge LabsSEC Form 410 March 2025Common Stock · traded 27 September 2024 · filed 10 March 2025
- was granted 90,000 shares of BioAge Labs (a derivative holding)SEC Form 420 February 2025Stock Option (Right to Buy) · traded 18 February 2025 · filed 20 February 2025
- was granted 40,000 shares of BioAge Labs (a derivative holding)SEC Form 420 December 2024Stock Option (Right to Buy) · traded 18 December 2024 · filed 20 December 2024
- exercised options over 6,060 shares of Precision Biosciences (a derivative holding)SEC Form 49 June 2023Restricted Stock Units · traded 7 June 2023 · filed 9 June 2023
- exercised options over 6,060 shares of Precision BiosciencesSEC Form 49 June 2023Common Stock · traded 7 June 2023 · filed 9 June 2023
- exercised options over 12,722 shares of Precision Biosciences (a derivative holding)SEC Form 47 March 2023Restricted Stock Units · traded 3 March 2023 · filed 7 March 2023
- exercised options over 12,722 shares of Precision BiosciencesSEC Form 47 March 2023Common Stock · traded 3 March 2023 · filed 7 March 2023
- was granted 70,000 shares of Precision Biosciences (a derivative holding)SEC Form 424 January 2023Restricted Stock Units · traded 20 January 2023 · filed 24 January 2023
- exercised options over 6,061 shares of Precision Biosciences (a derivative holding)SEC Form 49 June 2022Restricted Stock Units · traded 7 June 2022 · filed 9 June 2022
- exercised options over 6,061 shares of Precision BiosciencesSEC Form 49 June 2022Common Stock · traded 7 June 2022 · filed 9 June 2022
- was granted 60,604 shares of Precision Biosciences (a derivative holding)SEC Form 47 March 2022Employee Stock Option (Right to Buy) · traded 3 March 2022 · filed 7 March 2022
- was granted 38,161 shares of Precision Biosciences (a derivative holding)SEC Form 47 March 2022Restricted Stock Units · traded 3 March 2022 · filed 7 March 2022
- was granted 1,294 shares of Precision BiosciencesSEC Form 47 March 2022Common Stock · traded 26 February 2021 · filed 7 March 2022
- was granted 604 shares of Precision BiosciencesSEC Form 47 March 2022Common Stock · traded 31 August 2021 · filed 7 March 2022
- was granted 761 shares of Precision BiosciencesSEC Form 47 March 2022Common Stock · traded 28 February 2022 · filed 7 March 2022
- was granted 31,242 shares of Precision Biosciences (a derivative holding)SEC Form 49 June 2021Employee Stock Option (Right to Buy) · traded 7 June 2021 · filed 9 June 2021
- was granted 18,181 shares of Precision Biosciences (a derivative holding)SEC Form 49 June 2021Restricted Stock Units · traded 7 June 2021 · filed 9 June 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.